Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity: ...
Axios Sneak Peek on MSN52m
MAGA-approved climate policy lawsuit makes misleading claims
Three of the biggest investment firms in the world were sued by 11 states last week, in a case that not only could transform ...